Fig. 3

Protein signature for the classification of malignant breast cancer. A-B) Receiver operating characteristic (ROC) curves for the 17-protein malignancy score in the discovery (A) and validation (B) cohorts. The optimal Youden index point is marked in the plots (speficity and sensitivity 90% and 88%, respectively, in the discovery cohort, and 79% and 85% in the validation cohort). AUC, area under the curve. C-D) Box plots visualizing the distribution of the 17-protein malignancy score in invasive breast cancer samples and non-malignant fibroadenomas in the discovery (C) and validation (D) cohorts. The dashed line indicates the optimal cut-point (-4.7) of the score as determined by the ROC curve analysis